FDA Approves Revtorpyk for a Breast Cancer Subgroup That Had Been Left Out of Targeted Treatment
FDA approved Revtorpyk (gedatolisib) for HR+/HER2- PIK3CA wild-type advanced breast cancer. VIKTORIA-1 showed 9.3 months of PFS versus 2.0.
Medical Daily ·